摘要
目的观察多西他赛联合奥沙利铂和氟尿嘧啶治疗晚期食管癌近期疗效和不良反应。方法42例晚期食管癌患者给予多西他赛75mg／m2，静脉滴注1h，第1天；奥沙利铂100mg／m2，静脉滴注，第2天；氟尿嘧啶500mg／m2，静脉滴注，第1～5天；21d为1个周期，每例患者至少应用2个周期。每2个周期评价疗效。结果所有患者共完成163个周期治疗，其中完全缓解2例，部分缓解26例，稳定9例，进展5例，有效率为66．7％；中位进展时间6．7个月，生存期3．4～23．5个月，中位生存时间12．9个月；Ⅲ～Ⅳ度不良反应包括粒细胞计数减少（16．7％）、贫血（4．8％）、恶心、呕吐（2．4％）及血小板计数减少（2．4％）；无化疗相关性死亡。结论多西他赛联合奥沙利铂和氟尿嘧啶方案治疗晚期食管癌效果好，不良反应可难受。
Objective To observe the short-term effect and toxicity of docetaxe combined with oxaliplatin and fluorouracil in the treatment of advanced esophageal cancer. Methods Forty-two patients with advanced esophageal cancer received intravenous injection of docetaxe （75 mg/m2） for 1 hour on the first day, oxaliplatin （100 mg/m2） for 2 hours on the second day, and fluorouracil （500 mg/m2 ） from the first to the fifth day, for 21 days as one therapeutic cycle. Each patient received at least 2 cycles and the therapeutic effect was evaluated every two weeks. Results A total of 163 cycles were accomplished in 42 patients, in which there were 2 patients of complete remission, 26 of partial remission, 9 of stable disease and 5 of progressive disease. The effective rate was 66.7%. The median progressive time was 6.7 months and the median survival time 12.9 months. The adverse reactions in Ⅲ to Ⅳ degree included neutropenia （16.7%）, anemia （4. 8%）, nausea and vomiting （2. 4%） and thrombocytopenia （2. 4%）. No chemotherapy-related death was found. Conelusions Docetaxe combined with oxaliplatin and fluorouracil is effective for advanced esophageal carcinoma and the adverse reactions are tolerable.
出处
《中华实用诊断与治疗杂志》
2014年第2期197-199,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
青年科学基金项目(81302120)
河南省医学科技攻关计划项目(201303038)
河南省科技厅基础与前沿项目(122300410155)
关键词
食管癌
多西他赛
奥沙利铂
氟尿嘧啶
Esophageal cancer~ docetaxel~ oxaliplatin
fluorouracil
